Scholar Rock Holding Co. (NASDAQ:SRRK) Stock Holdings Lessened by Sphera Funds Management LTD.

Sphera Funds Management LTD. lowered its stake in Scholar Rock Holding Co. (NASDAQ:SRRK) by 45.9% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 90,193 shares of the company’s stock after selling 76,673 shares during the period. Sphera Funds Management LTD. owned approximately 0.10% of Scholar Rock worth $3,898,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of SRRK. Vanguard Group Inc. grew its position in Scholar Rock by 17.6% during the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company’s stock worth $205,013,000 after purchasing an additional 708,817 shares in the last quarter. Principal Financial Group Inc. purchased a new position in Scholar Rock during the 4th quarter worth approximately $274,000. Blackstone Inc. purchased a new position in Scholar Rock during the 4th quarter worth approximately $910,000. Rhumbline Advisers grew its position in Scholar Rock by 13.2% during the 4th quarter. Rhumbline Advisers now owns 113,261 shares of the company’s stock worth $4,895,000 after purchasing an additional 13,247 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Scholar Rock during the 4th quarter worth approximately $2,625,000. Institutional investors own 91.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Wedbush reiterated an “outperform” rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Wednesday. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Scholar Rock presently has a consensus rating of “Buy” and an average target price of $42.67.

Insider Activity

In other news, CEO Jay T. Backstrom sold 18,372 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $36.83, for a total transaction of $676,640.76. Following the completion of the transaction, the chief executive officer now owns 311,991 shares of the company’s stock, valued at approximately $11,490,628.53. This represents a 5.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tracey Sacco sold 5,000 shares of the company’s stock in a transaction dated Friday, April 25th. The shares were sold at an average price of $32.83, for a total transaction of $164,150.00. Following the transaction, the insider now directly owns 71,750 shares of the company’s stock, valued at $2,355,552.50. This represents a 6.51% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 255,231 shares of company stock valued at $9,220,236. Insiders own 13.30% of the company’s stock.

Scholar Rock Stock Up 0.9%

SRRK stock opened at $30.83 on Friday. The company has a current ratio of 3.88, a quick ratio of 3.88 and a debt-to-equity ratio of 0.63. Scholar Rock Holding Co. has a 1 year low of $6.76 and a 1 year high of $46.98. The company has a fifty day simple moving average of $31.26 and a 200 day simple moving average of $35.87. The firm has a market cap of $2.92 billion, a PE ratio of -13.12 and a beta of 0.37.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.04). Sell-side analysts anticipate that Scholar Rock Holding Co. will post -2.42 EPS for the current fiscal year.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.